(a) As previously reported, on November 11, 2016, Mateon Therapeutics, Inc. (the “Company”) held a Special Meeting of the stockholders of the Company (the “Special Meeting”) which was adjourned to November 22, 2016 to allow further solicitation of votes in favor of a proposal regarding a reverse stock split of the Company’s common stock.

(b) At the Special Meeting held on November 22, 2016, of the 26,544,934 shares of the Company’s common stock entitled to vote, 17,093,808 shares were represented at the meeting in person or by proxy, constituting a quorum. The voting results relating to the reverse stock split are as set forth below. This proposal is described in further detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 3, 2016 (the “Proxy Statement”).

The stockholders did not approve a proposal authorizing the filing of an amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, at a ratio in the range of 1:2 to 1:4, such ratio to be determined by the Board of Directors consistent with the guidelines described in the Proxy Statement, and the filing of such amendment to be implemented, if at all, not later than November 27, 2016. Passage of this proposal required approval of the holders of a majority of the issued and outstanding capital stock, or 13,272,468 “for” votes.